Milk Thistle Liver Enzyme Randomized Trial: What the Evidence Says

Quick Answer

Milk Thistle Liver Enzyme Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 2 randomized trial.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Metabolic dysfunction-associated steatotic liver disease [MASLD; formerly known as non-alcoholic fatty liver disease (NAFLD)] is caused by chronic fat deposition in the liver and is the result of complex interactions involving metabolic dysregulation and insulin resistance. [Messier Helen (2026); evidence level 2]
• Some patients with MASLD will have metabolic dysfunction-associated steatohepatitis (MASH) which is characterized by hepatocellular ballooning and lobular inflammation. [Messier Helen (2026); evidence level 2]
• Chronic liver disease is emerging as a public health priority in India, with the incidence of metabolic dysfunction-associated steatotic liver disease ranging between 8 and 20% depending on the region and contributing to 10 to 15% of deaths due to chronic liver disease. [Patel Ghanashyam (2026); evidence level 2]
• Ginger has been found to support healthy liver function, and to have antioxidant properties. [Patel Ghanashyam (2026); evidence level 2]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For milk thistle liver enzyme randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Messier Helen (2026). Effectiveness and safety of an ayurvedic nutraceutical for improving clinical parameters of liver function in participants with metabolic dysfunction-associated steatotic liver disease: a randomized, placebo-controlled, preliminary phase 2 exploratory clinical trial. DOI: 10.3389/fnut.2026.1761666. PMCID: PMC13019736. PMID: 41909037. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13019736/
• Patel Ghanashyam (2026). Long-term safety and efficacy of a highly purified plant-based nutraceutical for improving clinical parameters of liver function in healthy participants: a randomized, double-blind, placebo-controlled clinical trial. DOI: 10.3389/fnut.2025.1721748. PMCID: PMC12875990. PMID: 41659807. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12875990/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.